Eucrates Biomedical Acquisition Corp. (EUCR) Stock

About Eucrates Biomedical Acquisition Corp.

Eucrates Biomedical Acquisition Corp. currently lacks substantial business operations. Its primary objective is to execute a corporate transaction such as a merger, stock swap, asset purchase, equity acquisition, restructuring, or another comparable strategic alliance involving one or more enterprises. Specifically, it aims to find and acquire a company operating within the life sciences or broader healthcare sectors across North America and Europe. Established in 2020, this entity has its headquarters situated in New York, New York.

Eucrates Biomedical Acquisition Corp. is headquartered in US.

Eucrates Biomedical Acquisition Corp. (EUCR) stock trades at $10.04 with a market capitalization of $42.23M. The stock is valued at a price-to-earnings (P/E) ratio of 5.40, price-to-book of 3.50, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $9.87 and $10.25, and currently trades 2.0% below its 52-week high.

On profitability, Eucrates Biomedical Acquisition Corp. generates a return on equity (ROE) of 10.27%, return on capital employed of -5.63%, an operating margin of 0.00%, a net profit margin of 0.00%.